Clinical Trial Search

Primary: Median Progression Free Survival (PFS) Time — 6.0; 7.6 months — p=<0.0001

Primary: Analysis of Change From Baseline to Day 15 in Maturation Index of the Vaginal Cell Type (Parabasal Cells) — -54.4; -4.8 Percentage of Parabasal Cells — p=<0.0001

Primary: Percentage of Subjects With a Greater Than or Equal to 50% Decrease in Sperm Concentration From Baseline to Week 26 — 1.5; 14.5 percentage of participants

Primary: Clinician-Administered PTSD Scale (CAPS) — 78.28; 80.44; 78.89 units on scale

Primary: One-year Survival — 50 percentage of participants

Primary: Plasma Concentration of Active Glucagon-like Peptide 1 (GLP-1) Before and After Sitagliptin Treatment — 7.0; 6.1; 10.6; 14.1 pmol/L

Primary: BMI Z-score Change — -0.057; 0.005 z-score — p=0.0967

Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…

Primary: Number of Participants With Safe Fixation of Mesh and Closure of Peritoneum by Clinical Investigation During Hospital Stay and Telephone Interview at Six Weeks…

Primary: Number of Subjects That Met the Individual Success Criteria — 19; 3 participants — p=<0.0001

Primary: Difference in the Proportion of Primary Outcome Successes Between Treatment Groups for Change in Combined Circumference Measurements — 20; 3 participants — p=<0.00005

Primary: Change of the SBMs From Baseline at Week 4 — 2.7; 2.7; 2.2; 2.4 times per week — p=0.352

Primary: Grade on the Burton et al. Acne Severity Grade Scale — 2 participants

Primary: SOFA (Sequential Organ Failure Assessment) Score — 0.7; 1.7 units on a scale

Primary: Study Part 1: Maximum Concentration (Cmax) of ETOR After Single Dosing — 12.39; 2.43; 27.30; 3.74 mg